STATE OF OKLAHOMA

1st Session of the 59th Legislature (2023)

SENATE BILL 217 By: Hamilton

AS INTRODUCED

An Act relating to health care; requiring licensed practitioners to offer pharmacogenomic test prior to prescription of psychotropic drugs; requiring certain disclosures and obtainment of informed consent; directing order and administration of pharmacogenomic test; providing for codification; and providing an effective date.

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

SECTION 1. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 7201 of Title 63, unless there is created a duplication in numbering, reads as follows:

A. A licensed practitioner shall, prior to the prescription of any psychotropic drug to a patient, offer to administer a pharmacogenomic test to the patient for the purpose of guiding the decisions of the licensed practitioner with respect to how the patient's genes may react to certain medications.

B. The licensed practitioner shall, to the best of the licensed practitioner's knowledge, inform the patient of the efficacy of pharmacogenomic testing. The licensed practitioner shall inform the

patient of whether or not the pharmacogenomic test to be administered is approved by the Food and Drug Administration. The licensed practitioner shall obtain the patient's informed consent prior to ordering a pharmacogenomic test. If the practitioner is aware of the cost of the pharmacogenomic test, the practitioner shall provide an estimate to the patient of such cost.

C. If a patient provides informed consent to receive a pharmacogenomic test, the licensed practitioner shall order the pharmacogenomic test and administer such test to the patient prior to the prescription of any psychotropic medication.

SECTION 2. This act shall become effective November 1, 2023.

59-1-1358 DC 1/9/2023 5:41:08 PM